NASDAQ:LRMR • US5171251003
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LARIMAR THERAPEUTICS INC (LRMR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-02-25 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-02 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-30 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-30 | Baird | Maintains | Outperform -> Outperform |
| 2025-08-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-08-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-06-24 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-03-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-25 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-29 | Truist Securities | Initiate | Buy |
| 2025-01-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-16 | Oppenheimer | Initiate | Outperform |
| 2024-10-03 | Wedbush | Initiate | Outperform |
| 2024-10-02 | HC Wainwright & Co. | Initiate | Buy |
| 2024-09-12 | Jones Trading | Initiate | Buy |
| 2024-09-04 | Baird | Initiate | Outperform |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 1,368.04% | N/A 453.25% | N/A 85.98% | N/A 76.37% | N/A 2.57% | N/A -23.80% | N/A 5.91% | |||||||||||
| EBITDA YoY % growth | -73.743M | -58.013M 21.33% | -52.811M 8.97% | -60.861M -15.24% | -39.838M 34.54% | -42.649M -7.06% | -50.139M -17.56% | -36.208M 27.78% | -41.447M -14.47% | -90.572M -118.52% | N/A -65.64% | N/A -2.87% | N/A 2.94% | N/A 58.69% | N/A 256.42% | N/A 244.55% | N/A 58.36% | N/A 18.58% | N/A | |
| EBIT YoY % growth | -73.813M | -58.225M 21.12% | -52.999M 8.98% | -61.122M -15.33% | -40.101M 34.39% | -42.804M -6.74% | -50.465M -17.90% | -36.526M 27.62% | -41.758M -14.32% | -90.89M -117.66% | N/A -69.21% | N/A -15.97% | N/A 4.10% | N/A 81.20% | N/A 656.80% | N/A 179.66% | N/A -22.87% | N/A 18.74% | N/A -28.91% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -33.24 | -25.44 23.47% | -22.92 9.91% | -23.40 -2.09% | -13.20 43.59% | -3.94 70.15% | -2.97 24.62% | -1.54 48.15% | -0.85 44.81% | -1.30 -52.94% | N/A -53.18% | N/A 6.16% | N/A 16.13% | N/A 12.78% | N/A -32.09% | N/A 29.94% | N/A 33.87% | N/A 47.56% | N/A 53.49% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 -11.03% | -0.49 -6.81% | -0.49 -18.31% | -0.48 21.89% | -0.50 0.68% | -0.50 -1.10% | -0.47 3.48% | -0.46 4.20% | -0.42 16.34% |
| Revenue Q2Q % growth | N/A | 7.164M | 12.818M | 12.637M | |||||
| EBITDA Q2Q % growth | -34.813M -12.39% | -35.143M -13.00% | -37.391M -35.39% | -39.246M 20.29% | -45.696M -31.26% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -43.091M -37.70% | -42.906M -37.57% | -43.103M -55.09% | -43.305M 12.51% | -45.339M -5.22% | N/A | N/A | N/A | N/A |
All data in USD
17 analysts have analysed LRMR and the average price target is 15.5 USD. This implies a price increase of 197.01% is expected in the next year compared to the current price of 5.22.
LARIMAR THERAPEUTICS INC (LRMR) will report earnings on 2026-03-18, after the market close.
The consensus EPS estimate for the next earnings of LARIMAR THERAPEUTICS INC (LRMR) is -0.5 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering LARIMAR THERAPEUTICS INC (LRMR) is 17.